outperform
reason report
bottom line downgrad mp lower
pt preliminari treatment volum disclosur
line delay earn call cancel indic
fundament headwind coupl new propos
dialysi possibl legisl rate risk state even outsid
california materi reduc convict name see secular
headwind compani specif headwind like persist
delay earn guidanc increas
financi uncertainti potenti restat
announc delay possibl restat
earn sec review led audit committe reexamin
revenu recognit reserv relat revenu account
receiv time given potenti file exhibit
announc avail follow link
push reduc annual dialysi spend
increas dialysi medicar beneficiari creat
structur headwind appear behind peer
dialysi invest growth model larg focus
physician jv de novo open drive growth recent
announc paus de novo growth due dialysi pressur
made invest home remot monitor
overal dialysi popul expect grow shift could
present treatment growth headwind meanwhil note could
grow penetr exhibit pleas see note push
dialysi winner loser link
ev ebitda multipl
net debt total capit
price-to-earnings lt ep growth
compani inform svb leerink llc research
net revenu mm
pleas refer page import disclosur price chart analyst certif
legisl risk ca limit dialysi reimburs could lead
state enact similar legisl though ca exposur
minim veto former governor jerri brown last fall
push reviv legisl would limit dialysi
reimburs ab medicar reimburs ca
assembl member believ new governor gavin newsom
less like veto legisl minim ca exposur
five clinic believ larger risk state could follow
ca lead limit dialysi reimburs previou note ca
legisl avail follow
year price history/av daili volume mil
believ lower near-term treatment growth outlook
slower de novo open could manifest long term
industri shift clinic-bas treatment lower cost retail
home-bas set lower treatment growth
outlook bp near term due time de novo ramp
plan de novo open believ
lower treatment growth could becom perman structur
industri shift move dialysi treatment away clinic set still
note de novo pipelin consist deal open
estim execut plan deal
near term initi normal treatment growth
line estim bottom end guidanc estim
acceler exhibit
lower reimburs op network remain
headwind less clear in-network
transform volum tailwind believ mm
headwind estim includ upsid volum
improv contract though could price
pressur commerci payor go network
per treatment improv mircera calcimimet
transient tailwind though could opportun
improv esa transit aranesp mircera annual
benefit expect becom appar add one-year
tailwind calcimimet also posit impact ebitda
normal exhibit
believ reduct legal expens could lead
leverag reduct potenti invest home dialysi
partial off-set headwind leverag remain
believ deploy could divert improv home
technolog remot monitor believ
unlik impact restat exhibit
downgrad mp lower pt pt
contempl ev/ebitda averag believ
next upcom catalyst earn guidanc releas
date confer call tba exhibit
downgrad mp lower pt preliminari
treatment volum disclosur line delay earn call
cancel signal fundament headwind coupl new propos
dialysi possibl legisl rate risk state even outsid california materi
reduc convict name see secular headwind compani specif
headwind like persist margin expans thesi seem challeng
announc delay possibl restat earn sec
review led audit committe reexamin revenu recognit reserv relat
revenu account receiv financi impact unclear time believ
financi uncertainti increas potenti restat lower growth trajectori
believ lower near-term treatment growth outlook due slower de novo
open could manifest long term industri shift clinic-bas treatment
lower cost retail home-bas set yet determin reimburs
headwind network transform volum tailwind per treatment
improv mircera calcimimet transient tailwind though could
opportun improv believ reduct legal expens could
lead leverag reduct potenti invest home dialysi partial off-set
delay earn guidanc increas financi uncertainti
potenti restat announc delay possibl
restat earn sec review led audit committe reexamin
revenu recognit reserv relat revenu account receiv time
given potenti file announc avail follow link
push reduc annual dialysi spend increas dialysi
medicar beneficiari creat structur headwind appear behind
peer dialysi invest growth model larg focus physician
jv de novo open drive growth recent announc paus de novo
growth due dialysi pressur made invest home remot
monitor overal dialysi popul expect grow shift could
present treatment growth headwind meanwhil note could grow
pleas see note push dialysi winner loser link
previous disclos octob staff secur exchang commiss sec request compani voluntarili provid document inform relat certain revenu recognit collect relat matter follow receipt sec request compani respond produc document inform staff expect continu cooper sec provid addit document inform staff futur addit audit committe audit committe board director compani began examin compani revenu recognit methodolog relat account matter intern control financi report relat revenu recognit relat matter assist legal counsel report audit committe well independ account advisor retain audit committe counsel audit committe review continu assist advisor audit committe examin reserv comput account practic could impact account receiv revenu fiscal year end decemb well previous report fiscal year end decemb fiscal quarter within fiscal year first three fiscal quarter audit committe continu evalu whether adjust affect individu quarter year affect period compani expect comment audit committe review complet american renal associ hold inc
legisl risk ca limit dialysi reimburs could lead state enact
similar legisl though ca exposur minim veto former governor
jerri brown last fall push reviv legisl would limit
dialysi reimburs ab medicar reimburs ca assembl
member believ new governor gavin newsom less like veto legisl
minim ca exposur five clinic believ larger risk state could
follow ca lead limit dialysi reimburs previou note ca legisl
avail follow
believ lower near-term treatment growth outlook slower de novo open
could manifest long term industri shift clinic-bas treatment
lower cost retail home-bas set lower treatment growth
outlook bp near term due time de novo ramp plan
de novo open believ lower treatment growth could becom
perman structur industri shift move dialysi treatment away clinic set still
note de novo pipelin consist deal open
estim execut plan deal near term initi normal
treatment growth line estim bottom end guidanc
estim acceler
believ earn expect remain low addit financi
restat see downsid risk given secular dialysi headwind continu
preview avail follow link
guidanc rang
leerink consensu ebitda less nci end treatment base guidanc american renal associ hold inc
driver ebitda less nci report ebitda less treatment revenu per treat growth volum volum ramp de novosmircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate continu one year outsid bundletreat cost wage pressur yoycommerci mix headwind mix stabil contract mm headwind networkintern health increas cost intern health plang initi lobbi lobbi mainli svb leerink ebitda less headwindstailwindsdriv ebitda less nci report ebitda less assum treatment growth tailwind de novosmedicar rate base per treatment yoymircera margin margin improv mircera year transitioncalcimimet rate yoy upsid rate normal cost wage pressur yoy increas suppli cost increas contract mm headwind svb leerink ebitda less tailwindsheadwind american renal associ hold inc
lower reimburs network remain headwind less
clear in-network transform volum tailwind believ
mm headwind estim includ upsid volum improv
contract though could price pressur commerci
payor go network
per treatment improv mircera calcimimet transient tailwind
though could opportun improv esa transit aranesp
mircera annual benefit expect becom appar add one-year
tailwind calcimimet also posit impact ebitda normal
continu make solid progress expens side adopt esa altern
mircera septemb physician chosen convert mircera primari esa nearli
two-third clinic base strong physician interest long-act esa still expect
physician clinic convert mircera year-end
joseph carlucci chairman ceo co-found
think say two-third clinic convert mircera typic patient within
clinic convert doctor choic case true think could roughli
say two-third treatment mircera
think said clarifi low-singl dollar per treatment cost save mircera
someth reconfirm plan mircera turn pretti plan
year still expect exit year physician adopt
mircera say certainli benefit call relat employe health
benefit cost varianc approxim year-to-d sort take low-singl
dollar benefit talk essenti off-set unfortun trend
continu expect calcimimet posit transit
medicar environ calcimimet expect dynam due addit coverag
non-medicar payer introduct gener version sensipar chang practic pattern
respect iv drug parsabiv oral drug sensipar clinician gain experi
drug dialysi set
like close clinic section updat relat recent progress calcimimet
transit start januari implement medicar reimburs oral sensipar
new iv calcimimet call parsabiv transit drug add-on payment adjust
calcimimet prescrib dialysi patient control secondari hyperparathyroid
drug import therapi manag bone miner health transit continu
manag well clinic oper alway physician choic write prescript
order suppli item physician perspect work best patient
believ reduct legal expens could lead leverag reduct
potenti invest dialysi partial off-set headwind leverag remain
believ deploy could divert improv home
technolog remot monitor believ unlik impact
restat
net leverag came
downgrad mp lower pt pt contempl
ev/ebitda averag believ next upcom catalyst earn guidanc
releas date confer call tba
pt contempl ev ebitda multipl ebitda less nci estim
mm
pt contempl ev/ebitda averag ebitda less
downsid risk valuat includ
substanti reduct govern reimburs
lower margin shift patient privat insur provid medicar
govern program advers consequ new on-going litig
network contract seek go network
futur unfavor polici chang dialysi
execut challeng adopt mircera calcimimet
delay file increas financi uncertainti
incom statement mm except patient servic oper administr ebitda growth ebitda nci margin net incom incom tax less tax net incom attribut growth margin net outstand earn per growth growth american renal associ hold inc
